taysha gene therapies

Keyword	CPC	PCC	Volume	Score	Length of keyword
taysha gene therapies	0.42	0.7	6174	23	21
taysha	0.96	0.1	7051	82	6
gene	0.83	0.9	4298	24	4
therapies	0.68	0.6	8326	24	9

Keyword	CPC	PCC	Volume	Score
taysha gene therapies	1.46	1	5802	47
taysha gene therapies stocktwits	1.05	0.8	9423	85
taysha gene therapies news	1.61	0.5	3072	83
taysha gene therapies stock price	1.89	0.2	5190	90
taysha gene therapies layoffs	1.63	0.8	2526	24
taysha gene therapies price prediction	1.57	0.6	656	92
taysha gene therapies yahoo finance	0.26	0.5	7689	26
taysha gene therapies pipeline	1.33	0.9	8132	38
taysha gene therapies durham address	1.53	1	6951	49
taysha gene therapies inc tsha	0.61	0.7	913	52
taysha gene therapies astellas	0.66	0.5	6674	52
taysha gene therapies inc	1.72	0.9	6866	61
taysha gene therapies inc news	0.68	1	1627	52

Search Results related to taysha gene therapies on Search Engine

Taysha GTx
tayshagtx.com:443

https://tayshagtx.com:443/

WebAt Taysha Gene Therapies, we believe that with a steadfast focus on the targeted execution of our gene therapy programs, we can dramatically improve the lives of patients living with diseases of the central nervous system (CNS) caused by the mutation of a single gene, known as a monogenic disease.

DA: 21 PA: 50 MOZ Rank: 35

About Us | Taysha GTx
tayshagtx.com:443

https://tayshagtx.com:443/about-us/

WebMar 13, 2024 · Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations. The team’s primary focus is advancing our lead clinical program in Rett syndrome, and our pipeline of CNS …

DA: 30 PA: 34 MOZ Rank: 57

Pipeline | Taysha GTx
tayshagtx.com:443

https://tayshagtx.com:443/pipeline/

WebTaysha has a pipeline of early-stage gene therapy programs targeting CNS diseases that we may progress in the future or advance through potential partnerships. We have deprioritized the company sponsored evaluation of certain clinical-stage programs, including TSHA-105 for SLC13A5 and TSHA-118 for CLN1, and are seeking external strategic ...

DA: 15 PA: 77 MOZ Rank: 82

Buy Rating on Taysha Gene Therapies with TSHA-102 Poised to …
businessinsider.com:443

https://markets.businessinsider.com:443/news/stocks/buy-rating-on-taysha-gene-therapies-with-tsha-102-poised-to-transform-rett-syndrome-treatment-and-drive-revenue-growth-1033233129

WebApr 9, 2024 · Taysha Gene Therapies has received a new Buy rating, initiated by Piper Sandler analyst, Christopher Raymond.Christopher Raymond has given his Buy rating due to a combination of factors including ...

DA: 38 PA: 98 MOZ Rank: 51

Taysha Gene Therapies Announces Initiation of Clinical …
tayshagtx.com:443

https://ir.tayshagtx.com:443/news-releases/news-release-details/taysha-gene-therapies-announces-initiation-clinical-0

WebMar 29, 2022 · Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the initiation of clinical …

DA: 50 PA: 88 MOZ Rank: 38

Investors & Media | Taysha Gene Therapies
tayshagtx.com:443

https://ir.tayshagtx.com:443/

WebMar 1, 2024 · Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved …

DA: 80 PA: 91 MOZ Rank: 21

Taysha Gene Therapies Reports Initial Clinical Data from First …
tayshagtx.com:443

https://ir.tayshagtx.com:443/news-releases/news-release-details/taysha-gene-therapies-reports-initial-clinical-data-first-adult

WebDALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the second quarter ended June 30, …

DA: 16 PA: 21 MOZ Rank: 92

Taysha Gene Therapies Reports Positive Clinical Efficacy and …
tayshagtx.com:443

https://ir.tayshagtx.com:443/news-releases/news-release-details/taysha-gene-therapies-reports-positive-clinical-efficacy-and

Web01-31-2022 |. PDF Version. Efficacy data for high dose cohort demonstrated clinically meaningful and statistically significant improvement in MFM32 by Year 1 compared to natural history (n=3) Long-term durability data across all therapeutic dose cohorts demonstrated a 10-point improvement in mean change in MFM32 by Year 3 compared to …

DA: 56 PA: 99 MOZ Rank: 93

Taysha Gene Therapies Announces Poster Presentation on
globenewswire.com:443

https://www.globenewswire.com:443/news-release/2024/01/22/2812972/0/en/index.html

WebJan 22, 2024 · Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from ...

DA: 2 PA: 51 MOZ Rank: 10

Our Science | Taysha GTx
tayshagtx.com:443

https://tayshagtx.com:443/our-science/

WebOur Science | Taysha GTx. Our approach aims to address unique challenges in gene therapy by bringing together advanced genetic medicine technologies with established tools. What is Gene Therapy? Monogenic diseases are caused by harmful changes – or mutations – to a single gene in an individual’s genetic code.

DA: 88 PA: 28 MOZ Rank: 9